The rise of GLP-1 weight loss jabs, commonly known as Ozempic or Wegovy, is quietly reshaping Britain's fine dining scene. At Michelin-starred restaurants where indulgence was once the norm, an increasing number of patrons are now leaving courses barely touched — a trend that poses both logistical and economic challenges for the industry.
According to a report in City A.M., diners at top London establishments have been observed confessing their use of the appetite-suppressing drugs in hushed tones, with some even announcing it on arrival. The drugs, which cost between £100 and £350 a month on private prescription, work by making users feel fuller faster, drastically reducing the amount they can eat. For restaurants charging hundreds of pounds for multi-course tasting menus, the implications are significant.
At Heston Blumenthal's three-Michelin-starred The Fat Duck, the restaurant now offers a 'Mindful Experience' — a reduced version of its standard tasting menu. Blumenthal, who has been prescribed Wegovy himself, has warned the drugs could 'kill the restaurant industry'. Other chefs report that staff are being trained to spot diners struggling with large portions and to offer to skip courses or provide doggy bags, though purées and intricate plated dishes do not travel well.
The trend is not limited to London's elite dining rooms. With an estimated 1.5 million Britons now using GLP-1 drugs for weight loss or diabetes management, the ripple effects are being felt across the hospitality sector. For UK households, the shift reflects broader changes in consumer behaviour: spending on dining out may decline as appetite suppression reduces the perceived value of expensive meals. For businesses, adapting menus and reducing portion sizes could help retain customers but may squeeze margins in an industry already battling high inflation and staffing costs.
While the Bank of England has not directly commented on the phenomenon, the broader economic backdrop — with base rate at 4.75% as of July 2026 — means consumer discretionary spending remains under scrutiny. The FTSE 100, which includes major pharmaceutical firms producing GLP-1 drugs, has seen steady gains in the healthcare sector, while hospitality stocks face headwinds. For savers and investors, the divergence between these sectors highlights the importance of diversification, though individuals should consult a qualified financial adviser before making any decisions.